Hematopoietic Cell Patents (Class 424/173.1)
-
Publication number: 20130195940Abstract: The present disclosure relates generally to methods and materials for modulating the recruitment of macrophages or monocytes to sites at which they may contribute to disease initiation or progression. Embodiments of the disclosure comprise providing a modulator of the activity of ICAM-3 or proximal to the site.Type: ApplicationFiled: October 5, 2011Publication date: August 1, 2013Applicant: Aston UniversityInventor: Andrew Devitt
-
Publication number: 20130195890Abstract: A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: AIMSCO LIMITEDInventor: AIMSCO LIMITED
-
Publication number: 20130189284Abstract: Provided are isolated complexes comprising a major histocompatibility complex (MHC) class II and a type I diabetes-associated autoantigenic peptide, the isolated complex having a structural conformation which enables isolation of a high affinity entity which comprises an antigen binding domain capable of specifically binding to a native conformation of a complex composed of the MHC class II and the type I diabetes-associated autoantigenic peptide; and isolated high affinity entities comprising an antigen binding domain capable of specifically binding the complex, wherein the isolated high affinity entity does not bind to the MHC class II in an absence of the diabetes-associated autoantigenic peptide, wherein the isolated high affinity entity does not bind to the diabetes-associated autoantigenic peptide in an absence of the MHC class II; and methods and kits using same for diagnostic and therapeutic purposes.Type: ApplicationFiled: July 14, 2011Publication date: July 25, 2013Applicant: Technion Research & Development Foundation Ltd.Inventors: Yoram Reiter, Rony Dahan
-
Publication number: 20130183377Abstract: The present invention relates to a synthetic immunogen represented by the general formula 1, useful for generating long lasting protective immunity against various intracellular pathogens which are the causative agents of tuberculosis, leishmaniasis, AIDS, trypanosomiasis, malaria and also allergy, cancer and a process for the preparation thereof. The developed immunogen is able to circumvent HLA restriction in humans and livestock. The invention further relates to a vaccine comprising the said immunogen for generating enduring protective immunity against various diseases. The said vaccine is targeted against intracellular pathogens, more particularly the pathogen M. tuberculosis in this case. In the present invention, promiscuous peptides of M. tuberculosis are conjugated to TLR ligands especially; Pam2Cys to target them mainly to dendritic cells and therefore elicit long-lasting protective immunity.Type: ApplicationFiled: September 14, 2011Publication date: July 18, 2013Applicants: UNIVERSITY OF MELBOURNE, COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Javed Naim Agrewala, Uthaman Gowthaman, David Jackson, Weiguang Zeng
-
Publication number: 20130183322Abstract: A method of treating a subject in need of a cell or tissue transplant is disclosed. The method comprising (a) transplanting a non-syngeneic cell or tissue transplant into the subject, wherein the transplant comprises bone marrow or lymphoid cells; and (b) administering to the subject a therapeutically effective amount of an immunosuppressive regimen comprising a Sphingosine 1-Phosphate Receptor Agonist, a B7 molecule inhibitor and a CD2/CD58 pathway inhibitor, thereby treating the subject.Type: ApplicationFiled: September 8, 2011Publication date: July 18, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Yair Reisner, Esther Bachar-Lustig, Dalit Tchorsh-Yutsis
-
Publication number: 20130171142Abstract: Provided herein are methods of administering anti-CD3 antibodies or antigen binding fragments to a human for decreasing weight gain or increasing weight loss. In certain embodiments, the human exhibits a body mass index (BMI) or greater than or equal to about 27. In certain embodiments, the anti-CD3 antibody or antigen binding fragment does not bind or has reduced binding to at least one class of Fc (gamma) receptor.Type: ApplicationFiled: October 20, 2010Publication date: July 4, 2013Inventors: Aoife Brennan, Charlotte Mckee, Lou Vaickus, Douglas Ringler
-
Publication number: 20130171137Abstract: Methods of using anti-FceRI or anti-IgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.Type: ApplicationFiled: September 14, 2011Publication date: July 4, 2013Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INCInventors: Edward E. Mitre, Marc P. Hübner
-
Patent number: 8475793Abstract: The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Rene De Waal Malefyt, Leonard G. Presta
-
Publication number: 20130164214Abstract: Disclosed herein are methods and compositions comprising anti-CD74 and/or anti-HLA-DR antibodies for treatment of GVHD and other immune dysfunction diseases. In preferred embodiments, the anti-CD74 and/or anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel conditioning regimen for preventing aGVHD and/or treating chronic GVHD, without altering preexisting anti-viral immunity.Type: ApplicationFiled: October 19, 2012Publication date: June 27, 2013Applicant: IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
Patent number: 8470318Abstract: The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a ? 2, 6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody.Type: GrantFiled: July 3, 2007Date of Patent: June 25, 2013Assignee: The Rockefeller UniversityInventors: Jeffrey V. Ravetch, Falk Nimmerjahn, Yoshikatsu Kaneko -
Publication number: 20130156794Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.Type: ApplicationFiled: November 5, 2012Publication date: June 20, 2013Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventor: Yeda Research and Development Co. Ltd.
-
Publication number: 20130156768Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.Type: ApplicationFiled: August 25, 2011Publication date: June 20, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Maria Jure-Kunkel, Jon Marc Wigginton, Ashok Kumar Gupta
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
-
Publication number: 20130149318Abstract: A PEG based hydrogel and a procedure for its topical application to the surface of the pia mater of the spinal cord that can be used for intrathecal delivery of diverse drug and biomolecular therapies for the treatment of traumatic central nervous system injuries and disorders including spinal cord injury (SCI), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are provided. This “painting of the pia” with biofunctionalized hydrogel material may be used as a prelude strategy in the therapeutic management of these CNS disorders. The strategy may be designed to create a microenvironment within the damaged regions of the spinal cord that is more conducive to the successful application of subsequent regeneration based treatments such as cell replacement therapies or endogenous regeneration and plasticity stimulation via application of growth factors or gene therapy.Type: ApplicationFiled: December 13, 2012Publication date: June 13, 2013Applicant: INVIVO THERAPEUTICS CORPORATIONInventor: InVivo Therapeutics Corporation
-
Publication number: 20130142807Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.Type: ApplicationFiled: January 25, 2013Publication date: June 6, 2013Applicant: Rigel Pharmaceuticals, Inc.Inventor: Rigel Pharmaceuticals, Inc.
-
Publication number: 20130136735Abstract: Methods of treatment to suppress an immune response are provided. The method comprises administering to a subject in need of treatment a naked blocking antibody that binds selectively iNKT cells in an amount effective to suppress the subject's iNKT cell function. Compositions comprising, an isolated, humanized antibody that binds selectively iNKT cells are also provided.Type: ApplicationFiled: October 26, 2012Publication date: May 30, 2013Applicant: NKT Therapeutics Inc.Inventor: NKT Therapeutics Inc.
-
Publication number: 20130136749Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: November 1, 2012Publication date: May 30, 2013Applicant: Medarex, Inc.Inventor: Medarex, Inc.
-
Publication number: 20130129751Abstract: The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.Type: ApplicationFiled: September 10, 2012Publication date: May 23, 2013Applicant: PROTOX THERAPEUTICS CORP.Inventor: J. Curtis Nickel
-
Publication number: 20130121958Abstract: The present invention provides an innovative versatile system, which allows delivery of one or several antigens or biologically active molecules into or onto targeted subset of cells. The invention is in particular directed to a combination of compounds and in particular to a composition, which comprises: (i) a fusion polypeptide comprising a streptavidin (SA) or avidin polypeptide and one or several effector molecule(s), wherein said fusion polypeptide retains the property of SA and avidin polypeptides to bind biotin; (ii) biotinylated targeting molecule(s), which are capable of targeting subset(s) of cells and/or cell surface molecule(s), and in particular dendritic cells (DC), subsets of DC and/or surface molecule(s) (including surface receptor(s)) of DC.Type: ApplicationFiled: December 12, 2010Publication date: May 16, 2013Applicants: INSTITUTE OF MICROBIOLOGY OF THE ASCR., V.V.I., INSTITUT PASTEURInventors: Claude Leclerc, Laleh Majlessi, Hui Dong, Peter Sebo, Ondrej Stanek
-
Publication number: 20130122080Abstract: A pharmaceutical composition of immuno-regulation or enhancement of immune response is disclosed, which includes a liposome and an immuno-regulating molecule or an antigenic molecule. The liposome, the immuno-regulating molecule or the antigenic molecule needs no genetic or chemical modification. The immuno-regulating molecule or the antigenic molecule is spontaneously adsorbed by the liposome. Thus, the formed pharmaceutical composition can be used for immuno-regulation or enhancement of immune responses.Type: ApplicationFiled: March 5, 2012Publication date: May 16, 2013Inventors: Kuang-Wen LIAO, Chia-Hung Chen
-
Publication number: 20130115228Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.Type: ApplicationFiled: October 22, 2012Publication date: May 9, 2013Applicant: TRUSTEES OF DARTMOUTH COLLEGEInventor: TRUSTEES OF DARTMOUTH COLLEGE
-
Publication number: 20130095121Abstract: Provided herein are methods of treating patients with immune-related diseases (e.g., diabetes) with immunotherapy.Type: ApplicationFiled: June 24, 2011Publication date: April 18, 2013Inventors: Aoife Brennan, Charlotte McKee, Lou Vaickus
-
Patent number: 8420086Abstract: Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other.Type: GrantFiled: August 19, 2011Date of Patent: April 16, 2013Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20130084289Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.Type: ApplicationFiled: November 20, 2012Publication date: April 4, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Patent number: 8409572Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic purpura (ITP).Type: GrantFiled: March 30, 2012Date of Patent: April 2, 2013Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Roland Beliard, Dominique Bourel, Arnaud Glacet, Christophe De Romeuf, Nicolas Bihoreau, Emmanuel Nony
-
Publication number: 20130078263Abstract: Disclosed herein are methods and compositions comprising anti-HLA-DR antibodies for treatment of allogeneic and xenogeneic immune responses occurring in organ transplant rejection and other immune dysfunction diseases. In preferred embodiments, the anti-HLA-DR antibodies are effective to deplete antigen-presenting cells, such as dendritic cells. Most preferably, administration of the therapeutic compositions depletes all subsets of APCs, including mDCs, pDCs, B cells and monocytes, without significant depletion of T cells. In alternative embodiments, administration of the therapeutic compositions suppresses proliferation of allo-reactive T cells, while preserving cytomegalovirus (CMV)-specific, CD8+ memory T cells. The compositions and methods provide a novel therapeutic agent for suppressing or preventing allogeneic or xenogeneic immune responses, without altering preexisting anti-viral immunity.Type: ApplicationFiled: September 20, 2012Publication date: March 28, 2013Applicant: IMMUNOMEDICS, INC.Inventor: Immunomedics, Inc.
-
Publication number: 20130078262Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: Dyax Corp.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
-
Publication number: 20130078238Abstract: A method or composition comprising an anti-CD3 immune molecule for treatment of hepatitis in a subject.Type: ApplicationFiled: April 29, 2011Publication date: March 28, 2013Applicants: Hadasit Medical Research Services & Decvelopment Co. Ltd., NASVAX LTD.Inventors: Yaron Ilan, Ronald Ellis
-
Publication number: 20130071388Abstract: Methods and compositions are provided for the creation and screening of non-human animal models having many of the histologic characteristics of human psoriasis. Immunocompromised host animals are injected with a purified population of CD45Rb positive cells, which are tolerant of the host major histocompatibility antigens, but are mismatched at one or more minor antigens. The injected cells are stimulated with a pro-inflammatory cytokine, e.g. IL-12, and a polyclonal activating agent. The injected animals develop a chronic skin disorder that includes histological features observed in human psoriasis, e.g. rete pegs, severe acanthosis and infiltration of Th1 cells into the dermis.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: Abbott Biotherapeutics Corp.Inventor: Abbott Biotherapeutics Corp.
-
Patent number: 8398979Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 4, 2008Date of Patent: March 19, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20130064831Abstract: The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of immunotherapeutic agents e.g. CTLA-4 antagonists such as Ipilimumab or Tremelimumab in combination with one or more chemotherapeutic agents in cancer patients.Type: ApplicationFiled: May 16, 2011Publication date: March 14, 2013Inventor: Rachel Wallach Humphrey
-
Publication number: 20130058921Abstract: The present disclosure provides methods for treating multiple myeloma using a combination of autologous expanded and activated NK cells from the patient and an antibody that targets an antigen on myeloma cells and/or an antibody that targets the KIR antigen on NK cells, wherein the antibodies elicit ADCC toward myeloma cells. The present disclosure provides methods for treating multiple myeloma using a combination of autologous NK cells and the anti-CS1 antibody elotuzumab.Type: ApplicationFiled: October 30, 2009Publication date: March 7, 2013Inventor: Frits Van Rhee
-
Publication number: 20130058959Abstract: The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal.Type: ApplicationFiled: June 20, 2012Publication date: March 7, 2013Inventor: Robert Sackstein
-
Patent number: 8388971Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: GrantFiled: May 14, 2012Date of Patent: March 5, 2013Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Ramon Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20130052206Abstract: The invention provides methods and compositions for early diagnosis and treatment of a disease associated with a specific antibody by employing the detection of a cross-idiotypic epitope on the specific antibody to detect the cells that produce the antibody before the development of clinical symptoms of the disease.Type: ApplicationFiled: February 28, 2011Publication date: February 28, 2013Applicant: Vincent AgnelloInventor: Vincent Agnello
-
Publication number: 20130052196Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to inhibit a response in a T cell (e.g., a pro-liferative response) when such a T cell is concomitantly contacted, or has previously been contacted, with an APC, which APC is simultaneously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.Type: ApplicationFiled: January 20, 2011Publication date: February 28, 2013Applicant: TOLERX, INC.Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
-
Publication number: 20130045219Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: October 22, 2012Publication date: February 21, 2013Applicants: BIOGEN IDEC MA INC., UCB PHARMA S.A.Inventors: UCB Pharma S.A., Biogen Idec MA Inc.
-
Publication number: 20130045180Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.Type: ApplicationFiled: January 27, 2012Publication date: February 21, 2013Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
-
Publication number: 20130045218Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: August 13, 2012Publication date: February 21, 2013Applicants: Syntonix Pharmaceuticals, Inc., Dyax Corp.Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
-
Patent number: 8377440Abstract: The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.Type: GrantFiled: November 30, 2007Date of Patent: February 19, 2013Assignees: Selexys Pharmaceuticals Corporation, Oklahoma Medical Research FoundationInventors: Rodger P. McEver, Richard Alvarez, Ziad Kawar
-
Publication number: 20130039886Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: March 11, 2011Publication date: February 14, 2013Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, The University of Birmingham, of EdgbastonInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
-
Publication number: 20130039911Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.Type: ApplicationFiled: March 4, 2011Publication date: February 14, 2013Inventors: Atul Bedi, Rajani Ravi
-
Publication number: 20130034571Abstract: The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue.Type: ApplicationFiled: October 5, 2012Publication date: February 7, 2013Applicant: THE WASHINGTON UNIVERSITYInventor: THE WASHINGTON UNIVERSITY
-
Publication number: 20130028890Abstract: An object of the present invention is to provide a technique to distinguish between Treg cells and activated T cells in a live state. Another object of the present invention is to provide a pharmaceutical composition for immunostimulation that can reduce the number of Treg cells in vivo and effectively express the immune response of activated T cells. In the method of the present invention, Treg cells are detected from test cells containing (i) regulatory T cells and (ii) at least one type of cell selected from the group consisting of naive T cells and activated T cells, wherein expressions of folate receptor 4 on the surfaces of cells are measured and Treg cells are detected using the expressions as an indicator. The present invention uses anti-folate receptor 4 antibody or folate receptor 4-binding fragment as an active ingredient contained in a pharmaceutical composition for immunostimulation.Type: ApplicationFiled: September 14, 2012Publication date: January 31, 2013Applicants: RIKEN, KYOTO UNIVERSITYInventors: Shimon Sakaguchi, Keiji Hirota, Tomoyuki Yamaguchi
-
Patent number: 8361471Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.Type: GrantFiled: July 29, 2010Date of Patent: January 29, 2013Assignee: The Regents of the University of ColoradoInventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
-
Patent number: 8361472Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: August 17, 2010Date of Patent: January 29, 2013Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8361468Abstract: The present invention is directed to humanized antibodies which bind the human C5a receptor and their use as therapeutic and diagnostic agents. The present invention is further directed toward nucleic acid sequences which encode said humanized antibodies, and their expression in recombinant host cells. In particular, the present invention is directed towards humanized antibodies derived from murine antibody 7F3 which specifically binds to the human C5a receptor.Type: GrantFiled: August 20, 2012Date of Patent: January 29, 2013Assignee: G2 Inflammation Pty LtdInventors: Peter Whitfeld, David Zahra, Charles Reay Mackay
-
Publication number: 20130022623Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.Type: ApplicationFiled: June 29, 2012Publication date: January 24, 2013Applicant: Cellerant Therapeutics, Inc.Inventors: Holger Karsunky, Ying-Ping Jiang
-
Publication number: 20120328632Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: December 21, 2011Publication date: December 27, 2012Applicant: Genentech, Inc.Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Patent number: RE44389Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: October 17, 2012Date of Patent: July 23, 2013Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt